Prior to his recent appointment as Chief Scientific Officer at VLP Therapeutics, he served as VP for Development Operations and Research at ClearPath Vaccines, a company funded by Astellas Pharma to develop a multivalent, bioconjugate vaccine for Klebsiella and Pseudomonas. Prior to ClearPath Vaccines, he served as the Executive Vice President and Chief Scientific Officer of PaxVax, Inc. from 2012 to 2019. In 2014, the company acquired Vivotif, a live typhoid vaccine currently licensed in over 29 countries, and in 2015, PaxVax completed phase 3 studies and submitted a BLA for a live cholera vaccine licensed from the University of Maryland. Subsequent to a preapproval inspection by the FDA of the PaxVax GMP manufacturing facilities (with no 483 findings), the FDA licensed the cholera vaccine (Vaxchora) in 2016 and also provided PaxVax with a Priority Review Voucher. PaxVax also had clinical stage vaccine programs for HIV, influenza, chikungunya, and anthrax, and preclinical programs for Zika virus. PaxVax was acquired by Emergent Biosolutions (EBSI) in 2018.
Before joining PaxVax, he was the Chief Scientific Officer of Liquidia Technologies, a clinical stage company in the Research Triangle Park in North Carolina that is commercializing a unique nanoparticle technology capable of generating monodisperse particles of predetermined size, shape, and composition. Here he was responsible for basic and applied research as well as development programs focused on new approaches to protein, polysaccharide, and RNA-vectored vaccines.